Evidence map›Paper›PMID 33571627›Full record

ArticleBrain, behavior, and immunity2021

A wake-like state in vitro induced by transmembrane TNF/soluble TNF receptor reverse signaling.

Cheryl Dykstra-Aiello, Khia Min Sabrina Koh, Joseph Nguyen, Mengran Xue, Sandip Roy, James M Krueger

Open access · greenAbstract read
In one paragraph

Article in Brain, behavior, and immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Tripping on the edge of consciousness.Sleep advances : a journal of the Sleep Research Society · 2023
    Article
  7. Review
  8. iScience · 2022
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Cheryl Dykstra-AielloDepartment of Integrative Physiology and Neuroscience, Washington State University-Spokane, WA, United States. Electronic address: c.dykstra-aiello@wsu.edu.
Khia Min Sabrina KohDepartment of Integrative Physiology and Neuroscience, Washington State University-Spokane, WA, United States.
Joseph NguyenDepartment of Integrative Physiology and Neuroscience, Washington State University-Spokane, WA, United States.
Mengran XueDepartment of Electrical Engineering, Washington State University-Pullman, WA, United States.
Sandip RoyDepartment of Electrical Engineering, Washington State University-Pullman, WA, United States.
James M KruegerDepartment of Integrative Physiology and Neuroscience, Washington State University-Spokane, WA, United States.
Washington State University Spokane · USWashington State University · US

Funding

INTERLEUKIN-1--PROMOTER OF SLOW-WAVE SLEEPR01NS025378 · NINDS · WASHINGTON STATE UNIVERSITY · PI KRUEGER, JAMES MARTIN · 1987 to 2020
$6.3M
TNF signaling methods initiating in vitro sleep-like statesR21NS096250 · NINDS · WASHINGTON STATE UNIVERSITY · PI KRUEGER, JAMES MARTIN · 2016 to 2017
$420k
NINDS NIH HHS R01 NS025378NINDS NIH HHS R21 NS096250
6 · The paper itself

Abstract

Tumor necrosis factor alpha (TNF) has sleep regulatory and brain development roles. TNF promotes sleep in vivo and in vitro while TNF inhibition diminishes sleep. Transmembrane (tm) TNF and the tmTNF receptors (Rs), are cleaved by tumor necrosis factor alpha convertase to produce soluble (s) TNF and sTNFRs. Reverse signaling occurs in cells expressing tmTNF upon sTNFR binding. sTNFR administration in vivo inhibits sleep, thus we hypothesized that a wake-like state in vitro would be induced by sTNFR-tmTNF reverse signaling. Somatosensory cortical neuron/glia co-cultures derived from male and female mice lacking both TNFRs (TNFRKO), or lacking TNF (TNFKO) and wildtype (WT) mice were plated onto six-well multi-electrode arrays. Daily one-hour electrophysiological recordings were taken on culture days 4 through 14. sTNFR1 (0.0, 0.3, 3, 30, 60, and 120 ng/µL) was administered on day 14. A final one-hour recording was taken on day 15. Four measures were characterized that are also used to define sleep in vivo: action potentials (APs), burstiness index (BI), synchronization of electrical activity (SYN), and slow wave power (SWP; 0.25-3.75 Hz). Development rates of these emergent electrophysiological properties increased in cells from mice lacking TNF or both TNFRs compared to cells from WT mice. Decreased SWP, after the three lowest doses (0.3, 3 and 30 ng/µL) of the sTNFR1, indicate a wake-like state in cells from TNFRKO mice. A wake-like state was also induced after 3 ng/µl sTNFR1 treatment in cells from TNFKO mice, which express the TNFR1 ligand, lymphotoxin alpha. Cells from WT mice showed no treatment effects. Results are consistent with prior studies demonstrating involvement of TNF in brain development, TNF reverse signaling, and sleep regulation in vivo. Further, the current demonstration of sTNFR1 induction of a wake-like state in vitro is consistent with the idea that small neuronal/glial circuits manifest sleep- and wake-like states analogous to those occurring in vivo. Finally, that sTNF forward signaling enhances sleep while sTNFR1 reverse signaling enhances a wake-like state is consistent with other sTNF/tmTNF/sTNFR1 brain actions having opposing activities.

Indexed as

Receptors, Tumor Necrosis Factor, Type IITumor Necrosis Factor-alphaAnimalsFemaleMaleMiceNeurogliaNeuronsReceptors, Tumor Necrosis Factor, Type ISignal TransductionReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IITumor Necrosis Factor-alphaBrain developmentCytokineInterleukin-1In vitro sleepLocal sleepReverse signalingSleepTissue cultureTNFTNF receptorTumor necrosis factorWake

Identifiers

PMID33571627
PMCPMC8058269
OpenAlexW3128167302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.